Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gain Therapeutics Inc GANX

Healthcare Biotechnology
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug... see more

Recent & Breaking News (NDAQ:GANX)

Gain Therapeutics To Present At Biotech Showcase 2025

GlobeNewswire 11 days ago

Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

GlobeNewswire November 14, 2024

Gain Therapeutics Presents Data at 36ᵗʰ EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrating Identification of Allosteric Inhibitors Targeting DDR2

GlobeNewswire October 23, 2024

Gain Therapeutics Announces Poster Presentation at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 15, 2024

Gain Therapeutics to Present at Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference

GlobeNewswire October 9, 2024

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

GlobeNewswire October 7, 2024

Gain Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire October 3, 2024

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

GlobeNewswire September 30, 2024

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

GlobeNewswire September 26, 2024

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

GlobeNewswire September 19, 2024

Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 3, 2024

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

GlobeNewswire August 29, 2024

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

GlobeNewswire August 8, 2024

Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference

GlobeNewswire August 1, 2024

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

GlobeNewswire July 9, 2024

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

GlobeNewswire June 28, 2024

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

GlobeNewswire June 27, 2024

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

GlobeNewswire June 27, 2024

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

GlobeNewswire June 25, 2024

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

GlobeNewswire June 13, 2024